Anavex Life Sciences Corp (AVXL)

[seventhwave]

Doc328, all excellent points. You said...

If A2-73 works in AD, why aren't we trying to enroll the AD 2b/3 in a timely manner with more sites? ...... His response to the AD enrollment question at the last CC was incomprehensible and also signaled the deemphasis of AD.

In the following video, Missling clearly says the Alzheimer's study readout will be "in the forthcoming years." I'm pretty sure he had said 2021 previously but now he's not holding himself to the 2021 target.

(statement at 2:45 min)
I won't however call it a SHIFT in emphasis away from Alz. The PDD & Rett trials are shorter and in play which is why we are hearing about them more v/s Alz. where a slow recruitment process is under way. Missling should absolutely try his best to speed up the ALZ trial recruitment because of the large N. Maybe a successful PDD readout gets enough interest in Spain to subsidize recruitment in the Alz trial. There is way too much of a tug of war for Alz patients among competing Alz trials.
Missling's done a great job managing costs overall but the proce has been slower trial recruitment. Hard to believe the last real readout (Alz. p2a) was in Nov 2015 and we're all so starved at this point for the next topline.